Boston Scientific (BSX) Revenue — Quarter Ended Dec 31, 2023
Revenue for the quarter increased compared to both the preceding quarter and the same quarter last year. The company's top line continued its upward trajectory over the trailing twelve months.
Key takeaway
Quarter ended Dec 31, 2023 · FY2023 Q4
Revenue for the quarter increased compared to both the preceding quarter and the same quarter last year. The company's top line continued its upward trajectory over the trailing twelve months.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$3.7B
Revenue reported for this quarter.
Quarter-over-quarter
+5.6%
Change from the immediately preceding quarter.
Year-over-year
+14.9%
Change from the comparable year-ago quarter.
Trailing four quarters
$14.2B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Mar 31, 2023 | $3.4B | +12.0% |
| Jun 30, 2023 | $3.6B | +10.9% |
| Sep 30, 2023 | $3.5B | +11.3% |
| Dec 31, 2023 | $3.7B | +14.9% |
Revenue performance
The reported revenue shows a positive direction, reflecting growth relative to the immediate prior quarter and a larger gain versus the year-ago period.
Quarterly comparison
Revenue rose compared to the prior quarter, and the year-over-year comparison also showed a substantial increase. The sequential and annual improvements are consistent with the trend observed throughout the fiscal year.
What to watch
The filing disclosed litigation-related net credits and restructuring charges, which may be relevant to monitor in future periods.